S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
NASDAQ:CCXI

ChemoCentryx Stock Forecast, Price & News

$34.57
-0.44 (-1.26 %)
(As of 10/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$33.55
$35.84
50-Day Range
$13.53
$40.50
52-Week Range
$9.53
$70.29
Volume2.04 million shs
Average Volume3.10 million shs
Market Capitalization$2.42 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.46
30 days | 90 days | 365 days | Advanced Chart
Receive CCXI News and Ratings via Email

Sign-up to receive the latest news and ratings for ChemoCentryx and its competitors with MarketBeat's FREE daily newsletter.


ChemoCentryx logo

About ChemoCentryx

ChemoCentryx, Inc. is a biopharmaceutical company engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in San Carlos, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:CCXI
CUSIP
16383L10
Employees
133
Year Founded
N/A

Sales & Book Value

Annual Sales
$64.89 million
Book Value
$5.57 per share

Profitability

Net Income
$-55.36 million
Net Margins
-568.54%

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$2.42 billion
Next Earnings Date
11/8/2021 (Estimated)
Optionable
Optionable

MarketRank

Overall MarketRank

2.33 out of 5 stars

Medical Sector

236th out of 1,359 stocks

Pharmaceutical Preparations Industry

108th out of 666 stocks

Analyst Opinion: 4.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -












ChemoCentryx (NASDAQ:CCXI) Frequently Asked Questions

Is ChemoCentryx a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last twelve months. There are currently 1 hold rating, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ChemoCentryx stock.
View analyst ratings for ChemoCentryx
or view top-rated stocks.

What stocks does MarketBeat like better than ChemoCentryx?

Wall Street analysts have given ChemoCentryx a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ChemoCentryx wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting ChemoCentryx?

ChemoCentryx saw a drop in short interest in the month of September. As of September 15th, there was short interest totaling 3,730,000 shares, a drop of 16.6% from the August 31st total of 4,470,000 shares. Based on an average daily volume of 2,070,000 shares, the days-to-cover ratio is presently 1.8 days. Currently, 7.0% of the shares of the stock are sold short.
View ChemoCentryx's Short Interest
.

When is ChemoCentryx's next earnings date?

ChemoCentryx is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for ChemoCentryx
.

How were ChemoCentryx's earnings last quarter?

ChemoCentryx, Inc. (NASDAQ:CCXI) issued its earnings results on Sunday, August, 8th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.55) by $0.01. The biopharmaceutical company had revenue of $1.81 million for the quarter, compared to analyst estimates of $4.85 million. ChemoCentryx had a negative net margin of 568.54% and a negative trailing twelve-month return on equity of 33.17%. The company's quarterly revenue was down 96.3% compared to the same quarter last year. During the same quarter last year, the business earned $0.29 EPS.
View ChemoCentryx's earnings history
.

How has ChemoCentryx's stock been impacted by COVID-19?

ChemoCentryx's stock was trading at $41.54 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CCXI stock has decreased by 16.8% and is now trading at $34.57.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for CCXI?

8 analysts have issued twelve-month price objectives for ChemoCentryx's shares. Their forecasts range from $38.00 to $107.00. On average, they expect ChemoCentryx's stock price to reach $72.63 in the next year. This suggests a possible upside of 110.1% from the stock's current price.
View analysts' price targets for ChemoCentryx
or view top-rated stocks among Wall Street analysts.

Who are ChemoCentryx's key executives?

ChemoCentryx's management team includes the following people:
  • Thomas J. Schall, Chairman, President & Chief Executive Officer
  • Tausif Butt, Chief Operating Officer & Executive Vice President (LinkedIn Profile)
  • Susan M. Kanaya, Chief Financial Officer, Secretary & Director
  • Sangita Ghosh, Senior Vice President-Technical Operations
  • Markus J. Cappel, Treasurer & Chief Business Officer

What is Thomas J. Schall's approval rating as ChemoCentryx's CEO?

10 employees have rated ChemoCentryx CEO Thomas J. Schall on Glassdoor.com. Thomas J. Schall has an approval rating of 58% among ChemoCentryx's employees. This puts Thomas J. Schall in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ChemoCentryx own?

What is ChemoCentryx's stock symbol?

ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."

Who are ChemoCentryx's major shareholders?

ChemoCentryx's stock is owned by many different retail and institutional investors. Top institutional investors include Belvedere Trading LLC (0.06%) and Strs Ohio (0.02%). Company insiders that own ChemoCentryx stock include (International) Ltd Vifor, Geoffrey M Parker, James L Tyree, Markus J Cappel, Pui San Kwan, Susan M Kanaya, Tausif Butt, Thomas A Edwards and Thomas J Schall.
View institutional ownership trends for ChemoCentryx
.

Which major investors are selling ChemoCentryx stock?

CCXI stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio. Company insiders that have sold ChemoCentryx company stock in the last year include (International) Ltd Vifor, Geoffrey M Parker, James L Tyree, Markus J Cappel, Pui San Kwan, Thomas A Edwards, and Thomas J Schall.
View insider buying and selling activity for ChemoCentryx
or view top insider-selling stocks.

Which major investors are buying ChemoCentryx stock?

CCXI stock was bought by a variety of institutional investors in the last quarter, including Belvedere Trading LLC.
View insider buying and selling activity for ChemoCentryx
or or view top insider-buying stocks.

How do I buy shares of ChemoCentryx?

Shares of CCXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ChemoCentryx's stock price today?

One share of CCXI stock can currently be purchased for approximately $34.57.

How much money does ChemoCentryx make?

ChemoCentryx has a market capitalization of $2.42 billion and generates $64.89 million in revenue each year. The biopharmaceutical company earns $-55.36 million in net income (profit) each year or ($0.84) on an earnings per share basis.

How many employees does ChemoCentryx have?

ChemoCentryx employs 133 workers across the globe.

What is ChemoCentryx's official website?

The official website for ChemoCentryx is www.chemocentryx.com.

Where are ChemoCentryx's headquarters?

ChemoCentryx is headquartered at 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043.

How can I contact ChemoCentryx?

ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company can be reached via phone at (650) 210-2900 or via email at [email protected].


This page was last updated on 10/24/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.